Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Common-Size Income Statement

Paying user area

Try for free

Allergan PLC pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan PLC, common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net revenues
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights
Gross profit
Research and development
Selling and marketing
General and administrative
Amortization
Goodwill impairments
In-process research and development impairments
Asset sales and impairments, net
Operating loss
Interest income
Interest expense
Teva Share Activity
Sale of businesses
Debt extinguishment costs as part of the debt tender offer
Debt extinguishment other
Other-than-temporary impairments
Dividend income
Naurex recovery
Forward sale of Teva shares
Pfizer termination fee, Allergan plc only
Bridge loan commitment fee
Interest rate lock
Other
Other income (expense), net
Loss before income taxes and noncontrolling interest
(Provision) benefit for income taxes
Net loss from continuing operations, net of tax
Income (loss) from discontinued operations, net of tax
Net income (loss)
Income attributable to noncontrolling interest
Net income (loss) attributable to shareholders
Dividends on preferred shares
Net income (loss) attributable to ordinary shareholders

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Income statement item Description The company
Operating loss The net result for the period of deducting operating expenses from operating revenues. Allergan PLC operating loss as a percentage of net revenues decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Loss before income taxes and noncontrolling interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan PLC loss before income taxes and noncontrolling interest as a percentage of net revenues increased from 2017 to 2018 and from 2018 to 2019.
Net income (loss) attributable to shareholders The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan PLC net income (loss) attributable to shareholders as a percentage of net revenues decreased from 2017 to 2018 and from 2018 to 2019.